PEGylated dextran as long-circulating pharmaceutical carrier.

PEGylated dextran as long-circulating pharmaceutical carrier. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

PEGylated dextran as long-circulating pharmaceutical carrier. Abstract Text:

Anatoly N Lukyanov,Rishikesh M Sawant,William C Hartner,Vladimir P Torchilin,

Dextran-polyethylene glycol (PEG) conjugates were synthesized by activating dextran hydroxy groups with carbonyldiimidazole, introducing amino groups by attaching ethylenediamine, and reacting amino groups with a succinimidyl-activated derivative of PEG. Conjugates with an average of 12 and 21 PEG (5 kDa) residues per single dextran (73 kDa) molecule were prepared. These conjugates have circulation half-lives of 5.3 h and 7.0 h, respectively, compared to 4.0 h for non-PEGylated dextran. The modification of dextran with PEG inhibits the uptake of polymer by the major organ of the reticuloendothelial system, the liver. Dextran-PEG conjugates may represent a convenient platform for long-circulating pharmaceutical preparations.

PEGylated dextran as long-circulating pharmaceutical carrier. Publishing Authors By Initials

AN Lukyanov,RM Sawant,WC Hartner,VP Torchilin,

For similar biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics: tissue distribution research abstracts see: biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics: tissue distribution research

PUBMED ID PMID:

MEDLINE DATE:

PEGylated dextran as long-circulating pharmaceutical carrier. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of biomaterials science. Polymer edition

VOLUME: 15

Page Numbers: 621-30

Journal Abbreviation:

ISSN: 0920-5063

DAY: 20

MONTH: 02

YEAR: 2004

PEGylated dextran as long-circulating pharmaceutical carrier. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9007393

PEGylated dextran as long-circulating pharmaceutical carrier. Keywords Mesh Terms:

KEYWORDS: Tissue Distribution

MESH TERMS: pharmacokinetics

Chemical & Substance for Abstract: PEGylated dextran as long-circulating pharmaceutical carrier. Information

Substance Name: Dextrans

Registry Number: 9004-54-0

Grant and Affiliation Information for PEGylated dextran as long-circulating pharmaceutical carrier.

AFFILIATION: Department of Pharmaceutical Sciences, Bouve College of Health Sciences, 312 Mugar Building, Northeastern University, Boston, MA 02115, USA.

Country: Netherlands

AGENCY: United States NHLBI

GRANT: HL64395

ACRONYM: HL

MEDLINETA: J Biomater Sci Polym Ed

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

PEGylated dextran as long-circulating pharmaceutical carrier Related Publications

• "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
• "Smart" Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes.
• Antibody-modified liposomes for cancer chemotherapy.
• Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
• Bioengineering and Imaging Research Opportunities Workshop V: A summary on Imaging and Characterizing Structure and Function in Native and Engineered Tissues.
• Bioengineering and Imaging Research Opportunities Workshop V: a white paper on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop V: summary of findings on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop v: a summary.
• Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.
• Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
• Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
• Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
• Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
• Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.
• Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity.
• Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
• Nanocarriers.
• PEGylated dextran as long-circulating pharmaceutical carrier.
• Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
• Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux.
• Polymeric contrast agents for medical imaging.
• Preface. Fifth International Nanomedicine and Drug Delivery Symposium (NanoDDS'07).
• Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.
• Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology.
• Surface Modification of Pharmaceutical Nanocarriers with Ascorbate Residues Improves their Tumor-Cell Association and Killing and the Cytotoxic Action of Encapsulated Paclitaxel In Vitro.
• TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
• Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers.
• Tatp-mediated intracellular delivery of pharmaceutical nanocarriers.
• The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.
• Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice.